- Apogee Therapeutics (NASDAQ: APGE) is being acquired by AbbVie (NYSE: ABBV) for approximately $10.9 billion, a strategic move aimed at expanding AbbVie’s immunology drug portfolio.
- Analyst firm Craig-Hallum downgraded Apogee Therapeutics stock from a “Buy” to a “Hold” rating, citing the limited upside potential for investors given the acquisition offer.
- Despite the downgrade, Apogee’s stock surged, reaching a new 52-week high, though the acquisition’s fairness is now under legal investigation by Halper Sadeh LLC.
Apogee Therapeutics, a clinical-stage biotechnology company, focuses on developing treatments for inflammatory and immunological diseases. This innovative biotech stock is being acquired by the large biopharmaceutical firm AbbVie for about $10.9 billion in cash. As highlighted by The Wall Street Journal, AbbVie is making this strategic purchase to strengthen its portfolio of immunology drugs.
The central event driving recent market discussion is a rating change from the analyst firm Craig-Hallum on June 22, 2026. The firm downgraded Apogee Therapeutics from a “Buy” to a “Hold” rating. This “Hold” rating suggests that analysts expect the stock performance to align with the broader market, indicating limited room for significant stock price changes.
This stock downgrade occurs as Apogee Therapeutics’ stock price stands at $132.62. The change in rating is a direct response to the acquisition offer from AbbVie of $135.11 per share. With the stock trading very close to the offer price, there is little potential for further investor gains, thereby justifying the “Hold” status.
As highlighted by Barron’s, the acquisition news caused Apogee Therapeutics’ stock to soar, increasing by $42.27, or 46.77%, in one day. The biotech stock reached a new 52-week high of $133.00. This surge brings the company’s total value, or market capitalization, to approximately $8.21 billion based on the high trading volume.
Adding a layer of complexity to the acquisition deal, the investor rights law firm Halper Sadeh LLC is investigating the sale. The firm is examining if Apogee Therapeutics and its board failed to secure the best possible price for shareholders. This investigation questions the fairness of the sales process and whether all important information was adequately disclosed.
